<DOC>
	<DOCNO>NCT01512693</DOCNO>
	<brief_summary>This open-label , non-randomized study design compare pharmacokinetics single 50 milligram ( mg ) dose MK-0822 participant without moderate hepatic insufficiency ( abnormal liver function ) order determine degree hepatic dysfunction may impact therapeutic blood level MK-0822 .</brief_summary>
	<brief_title>Assessment Pharmacokinetics Single Dose Odanacatib ( MK-0822 ) Subjects With Moderate Hepatic Insufficiency ( MK-0822-070 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatic Insufficiency</mesh_term>
	<criteria>Not currently pregnant , nurse planning pregnant throughout course study ; agree use specified contraception per protocol requirement Body Mass Index ( BMI ) â‰¤ 39 kg/m^2 ( obese ) Judged good health ( healthy participant population ) Nonsmoker past 6months ; social smoker ( smoke le 10 cigarette within past 3 month ; per discretion study Investigator , quit smoking within past 3 month . Diagnosed chronic ( 6 month ) , stable ( acute episode illness within previous 2 month ) hepatic insufficiency ( liver dysfunction ) feature cirrhosis due cause ( moderate hepatic insufficiency participant population ) Possess ability understand study , grant voluntary inform consent willingly comply study requirement Does meet age requirement , mentally legally incapacitate , expect significant emotional problem , history clinically significant psychiatric disorder Has diagnose disease medical condition may pose risk participant may confound study result Compromised renal ( kidney ) function , significant organ system disease ( ) cancer ( ) Unable refrain anticipates use new medication , include prescription nonprescription drug herbal remedy Meets requirement study regard current medication profile include : prescribed medication , caffeine , alcohol , overthecounter drug , herbal nutritional product ; expect nonuse recreational ( illicit ) drug associate misuse , abuse and/or addiction Had surgery , donate 1 unit blood receive another investigational study medication within 4 week prior study 's first dose investigational product History multiple and/or severe allergy , lifethreatening reaction inability tolerate prescription nonprescription drug food</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>